Overview

Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions

Status:
Completed
Trial end date:
2002-02-01
Target enrollment:
Participant gender:
Summary
This is a bioequivalence study to compare the rate and extent of absorption of lamotrigine (test) and Lamictal® (reference)administered as a 1 x 200 mg tablet under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Teva Pharmaceuticals USA
Treatments:
Anticonvulsants
Lamotrigine